Ardelyx, Inc. (ARDX) Revenue by Segment & Business Profile
Product IBSRELA was 71.3% of Ardelyx, Inc.'s revenue across the 5 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARDXArdelyx, Inc.Follow ARDX — free
—
Price chart with a free account
- Market cap
- 767.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
What the company does
Ardelyx, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 5 business lines: Product IBSRELA (71%), Product XPHOZAH (26%), Product Supply Revenue (2%), Non Cash Royalty Related To Sale Of Future Royalties (1%) and others. Trailing twelve-month revenue: $450.9 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Revenue by geography
fiscal year 2025 · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 378M | 92.8% | +18.4% |
| Asia Pacific | 29M | 7.2% | +103.4% |
| North America | 0M | 0.1% | +338.5% |
Ardelyx, Inc. — questions
- What does Ardelyx, Inc. do?
- Ardelyx, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 5 business lines: Product IBSRELA (71%), Product XPHOZAH (26%), Product Supply Revenue (2%), Non Cash Royalty Related To Sale Of Future Royalties (1%) and others. Trailing twelve-month revenue: $450.9 million as of 2026-06-30.
- How does Ardelyx, Inc. make money?
- By the lines it reports in its SEC filings: Product IBSRELA 71.3%, Product XPHOZAH 26.4%, Product Supply Revenue 1.6%, Non Cash Royalty Related To Sale Of Future Royalties 0.6%, License 0.1% of revenue.
Every figure on this page comes from Ardelyx, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.